These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
174 related articles for article (PubMed ID: 38246910)
1. Development of small-molecular-based radiotracers for PET imaging of PD-L1 expression and guiding the PD-L1 therapeutics. Yang H; Zeng X; Liu J; Wen X; Liu H; Liang Y; Wang X; Fang J; Zhang Q; Li J; Zhang X; Guo Z Eur J Nucl Med Mol Imaging; 2024 May; 51(6):1582-1592. PubMed ID: 38246910 [TBL] [Abstract][Full Text] [Related]
2. Development of novel peptide-based radiotracers for detecting PD-L1 expression and guiding cancer immunotherapy. Zhu S; Liang B; Zhou Y; Chen Y; Fu J; Qiu L; Lin J Eur J Nucl Med Mol Imaging; 2024 Feb; 51(3):625-640. PubMed ID: 37878029 [TBL] [Abstract][Full Text] [Related]
3. A preclinical study: correlation between PD-L1 PET imaging and the prediction of therapy efficacy of MC38 tumor with Qin S; Yu Y; Guan H; Yang Y; Sun F; Sun Y; Zhu J; Xing L; Yu J; Sun X Aging (Albany NY); 2021 Apr; 13(9):13006-13022. PubMed ID: 33910164 [TBL] [Abstract][Full Text] [Related]
4. A Novel Small Cyclic Peptide-Based Liu H; Hu M; Deng J; Zhao Y; Peng D; Feng Y; Wang L; Chen Y; Qiu L Mol Pharm; 2022 Jan; 19(1):138-147. PubMed ID: 34910492 [TBL] [Abstract][Full Text] [Related]
5. Preclinical evaluation and pilot clinical study of [ Ma X; Zhou X; Hu B; Li X; Yao M; Li L; Qin X; Li D; Yao Y; Hou X; Liu S; Chen Y; Wang Z; Zhou W; Li N; Zhu H; Jia B; Yang Z Eur J Nucl Med Mol Imaging; 2023 Nov; 50(13):3838-3850. PubMed ID: 37555904 [TBL] [Abstract][Full Text] [Related]
6. Linear Peptide-Based PET Tracers for Imaging PD-L1 in Tumors. Zhang L; Zhang S; Wu J; Wang Y; Wu Y; Sun X; Wang X; Shen J; Xie L; Zhang Y; Zhang H; Hu K; Wang F; Wang R; Zhang MR Mol Pharm; 2023 Aug; 20(8):4256-4267. PubMed ID: 37368947 [TBL] [Abstract][Full Text] [Related]
7. PET Imaging of Tumor PD-L1 Expression with a Highly Specific Nonblocking Single-Domain Antibody. Lv G; Sun X; Qiu L; Sun Y; Li K; Liu Q; Zhao Q; Qin S; Lin J J Nucl Med; 2020 Jan; 61(1):117-122. PubMed ID: 31253743 [TBL] [Abstract][Full Text] [Related]
8. Practical Immuno-PET Radiotracer Design Considerations for Human Immune Checkpoint Imaging. Mayer AT; Natarajan A; Gordon SR; Maute RL; McCracken MN; Ring AM; Weissman IL; Gambhir SS J Nucl Med; 2017 Apr; 58(4):538-546. PubMed ID: 27980047 [TBL] [Abstract][Full Text] [Related]
9. In vivo positron emission tomography imaging for PD-L1 expression in cancer using aptamer. Choi YJ; Park JY; Cho YL; Chae JR; Cho H; Kang WJ Biochem Biophys Res Commun; 2022 Sep; 620():105-112. PubMed ID: 35780578 [TBL] [Abstract][Full Text] [Related]
10. [ Zhou M; Xiang S; Zhao Y; Tang Y; Yang J; Yin X; Tian J; Hu S; Du Y Eur J Nucl Med Mol Imaging; 2024 Jan; 51(2):369-379. PubMed ID: 37759096 [TBL] [Abstract][Full Text] [Related]
11. Synthesis and Preclinical Evaluation of a Robu S; Richter A; Gosmann D; Seidl C; Leung D; Hayes W; Cohen D; Morin P; Donnelly DJ; Lipovšek D; Bonacorsi SJ; Smith A; Steiger K; Aulehner C; Krackhardt AM; Weber WA J Nucl Med; 2021 Sep; 62(9):1228-1234. PubMed ID: 33517324 [TBL] [Abstract][Full Text] [Related]
12. One-step radiosynthesis and initial evaluation of a small molecule PET tracer for PD-L1 imaging. Miao Y; Lv G; Chen Y; Qiu L; Xie M; Lin J Bioorg Med Chem Lett; 2020 Dec; 30(24):127572. PubMed ID: 32979488 [TBL] [Abstract][Full Text] [Related]
13. Sensitive Positron Emission Tomography Imaging of PD-L1 Expression in Human Breast and Lung Carcinoma Xenografts Using the Radiometalated Peptide Ga-68-TRAP-WL12. Quigley NG; Steiger K; Färber SF; Richter F; Weichert W; Notni J Mol Pharm; 2024 Apr; 21(4):1827-1837. PubMed ID: 38291706 [TBL] [Abstract][Full Text] [Related]
14. A novel Ge S; Zhang B; Li J; Shi J; Jia T; Wang Y; Chen Z; Sang S; Deng S Bioorg Chem; 2023 Nov; 140():106785. PubMed ID: 37639759 [TBL] [Abstract][Full Text] [Related]
15. Multifunctional Probe Based on "Chemical Antibody-Aptamer" for Noninvasive Detection of PD-L1 Expression in Cancer. Kong S; Liu Q; Chen Y; Liang B; Zhou Y; Lin J; Xie M; Qiu L Mol Pharm; 2024 Jan; 21(1):255-266. PubMed ID: 38093483 [TBL] [Abstract][Full Text] [Related]
16. Immuno-PET imaging of Liu Q; Jiang L; Li K; Li H; Lv G; Lin J; Qiu L Cancer Immunol Immunother; 2021 Jun; 70(6):1721-1733. PubMed ID: 33386467 [TBL] [Abstract][Full Text] [Related]
17. Preparation and Bioevaluation of Hu X; Lv G; Hua D; Zhang N; Liu Q; Qin S; Zhang L; Xi H; Qiu L; Lin J Mol Pharm; 2023 Aug; 20(8):4228-4235. PubMed ID: 37409670 [TBL] [Abstract][Full Text] [Related]
19. Preclinical Study of a Fully Human Anti-PD-L1 Antibody as a Theranostic Agent for Cancer Immunotherapy. Xu M; Han Y; Liu G; Xu Y; Duan D; Liu H; Du F; Luo P; Liu Z Mol Pharm; 2018 Oct; 15(10):4426-4433. PubMed ID: 30133286 [TBL] [Abstract][Full Text] [Related]
20. First-in-Humans Evaluation of a PD-L1-Binding Peptide PET Radiotracer in Non-Small Cell Lung Cancer Patients. Zhou X; Jiang J; Yang X; Liu T; Ding J; Nimmagadda S; Pomper MG; Zhu H; Zhao J; Yang Z; Li N J Nucl Med; 2022 Apr; 63(4):536-542. PubMed ID: 34326125 [No Abstract] [Full Text] [Related] [Next] [New Search]